# A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment

> **NCT02921815** · — · COMPLETED · sponsor: **Celgene** · enrollment: 84 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Leukemia, Myeloid, Acute

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02921815
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-03
- **Primary completion:** 2014-08-31
- **Final completion:** 2014-08-31
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2022-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02921815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02921815, "A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02921815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*